Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (1): 6-11.doi: 10.6040/j.issn.1671-7554.0.2017.899
SHI Aiping, XU Gege, XIE Xinpeng
CLC Number:
| [1] Habel LA, Dignam JJ, Land SR, et al. Mammographic density and breast cancer after ductal carcinoma in situ[J]. J Natl Cancer Inst, 2004, 96(19): 1467-1472. [2] Golshan M, Cirrincione CT, Sikov WM, et al. Alliance for Clinical Trials in Oncology. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603(Alliance)[J]. Ann Surg, 2015, 262(3): 434-439. [3] Landercasper J, Bennie B, Parsons BM, et al. Fewer reoperations after lumpectomy for breast cancer with neoadjuvant rather than adjuvant chemotherapy: a report from the national cancer database[J]. Ann Surg Oncol, 2017, 24(6): 1507-1515. [4] Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer[J].Ann Surg Oncol, 2012, 19(10): 3177-3184. [5] Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer[J]. Br J Surg, 2007, 94(10): 1189-1200. [6] Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Natl Cancer Inst Monogr, 2001(30): 96-102. doi: 10.1093 /oxfordjournals.jncimonographs.a003469. [7] El-Didi MH, Moneer MM, Khaled HM, et al. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management[J]. Surg Today, 2000, 30(3): 249-254. [8] Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience[J]. J Clin Oncol, 2004, 22(12): 2303-2312. [9] Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2015, 22(4): 1118-1127. [10] Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype[J]. J Clin Oncol, 2011, 29(6): 660-666. [11] Mukhtar RA, Yau C, Rosen M, et al. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL(CALGB 150007/150012; ACRIN 6657)[J]. Ann Surg Oncol, 2013, 20(12): 3823-3830. [12] FelicianoY, Mamtani A, Morrow M, et al. Do calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised?[J]. Ann Surg Oncol, 2017, 24(6):1492-1498. [13] Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071(Alliance)clinical trial[J]. JAMA, 2013, 310(14): 1455-1461. [14] Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy(SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618. [15] Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264. [16] Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study[J]. Ann Surg Oncol, 2016, 23(11): 3467-3474. [17] Krag DN, Julian TB, Harlow SP, et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial[J]. Ann Surg Oncol, 2004, 11(3 Suppl): 208-210. [18] Chang JM, Kosiorek HE, Wasif N, et al. The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review[J]. Am J Surg, 2017, 214(6):1096-1101. [19] Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection[J]. J Clin Oncol, 2016, 34(10): 1072-1078. [20] Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281. [21] Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer(NSABP B-40[NRG Oncology] ): secondary outcomes of a phase 3, randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1037-1048. [22] Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study(GBG 44)[J]. Ann Oncol, 2013, 24(12): 2978-2984. [23] Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21. [24] Isakoff SJ, Mayer EL, He L, et al.TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer[J]. J Clin Oncol, 2015, 33(17): 1902-1909. [25] Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial[J]. JAMA Oncol, 2017, 3(10):1378-1385. [26] Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer(GeparSepto-GBG 69): a randomised, phase 3 trial[J]. Lancet Oncol, 2016, 17(3): 345-356. [27] Schettini F,Giuliano M,De Placido S,et al. Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives[J]. Cancer Treat Rev, 2016, 50: 129-141. doi: 10.1016/j.ctrv.2016.09.004. [28] Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups[J]. J Clin Oncol, 2011, 29(25): 3351-3357. [29] Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer(NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800. [30] Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006[J]. J Clin Oncol, 2013, 31(14): 1726-1731. [31] Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32. [32] Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study(TRYPHAENA)[J]. Ann Oncol, 2013, 24(9): 2278-2284. [33] Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2012, 379(9816): 633-640. [34] Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer(NSABP protocol B-41): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(12): 1183-1192. [35] Harbeck N, Gluz O, Christgen M, et al. De-escalation strategies in human epidermal growth factor receptor 2(HER2)-positive early breast cancer(BC): final analysis of the west german study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy(ET)versus trastuzumab plus ET[J]. J Clin Oncol, 2017, 35(26): 3046-3054 [36] Ellis MJ. Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer[J]. Breast, 2017, 34(Suppl 1): 104-107. [37] Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer[J]. Cancer, 2007, 110(2): 244-254. [38] Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics[J]. J Natl Cancer Inst, 2008, 100(19): 1380-1388. [39] Yeo B, Dowsett M. Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints[J]. Breast, 2015, 24(Suppl 2): 78-83. [40] Kolberg HC, Aktas B, Liedtke C. Clinical utility of neoadjuvant endocrine therapy for hormone receptor positive breast cancer[J]. Rev Recent Clin Trials, 2017, 12(2): 67-72. [41] Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial[J]. J Clin Oncol, 2001, 19(18): 3808-3816. [42] Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031[J]. J Clin Oncol, 2011, 29(17): 2342-2349. [43] Ellis MJ, Suman VJ, Hoog J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial(Alliance)[J]. J Clin Oncol, 2017, 35(10): 1061-1069. [44] Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22): 2147-2159. |
| [1] | RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30. |
| [2] | LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46. |
| [3] | HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43. |
| [4] | Qifeng YANG,Ning ZHANG. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5. |
| [5] | QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82. |
| [6] | ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24-29. |
| [7] | Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139. |
| [8] | WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118. |
| [9] | LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84. |
| [10] | KONG Xue, LI Juan, DUAN Weili, SHI Shuang, LI Peilong, DU Lutao, MAO Haiting, WANG Chuanxin. Effects of lncRNA AC012073.1 on the migration and invasion of human breast cancer cells and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 70-78. |
| [11] | YOU Xueting, TIAN Xingsong. Analysis of clinicopathological characteristics of 3 514 cases of breast cancer over 9 years [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 49-54. |
| [12] | ZHANG Xiqin, ZHU Shouhui, LIU Ning, WANG Yu, CHEN Jiazhen, HU Xudong. Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 43-46. |
| [13] | LIU Yinhua, ZHAO Jingyi, XIN Ling. Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 1-5. |
| [14] | LI Yanxiang, ZHANG Wenhua, YANG Feilong, FANG Liang, XU Zhonghua. The correlation between BRCA1 mRNA and protein expressions in epithelial urethra cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 91-94. |
| [15] | LIAN Kaili, LI Yan, ZHANG Na, JIN Guiyuan, LIU Suxia. TIPE3 decreases breast cancer cell sensitivity to adriamycin by upregulating P-gp protein expression [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 36-42. |
|
||
